A Novel Approach to Assay DNA Methylation in Prostate Cancer
Technical Report,30 Sep 2015,29 Sep 2016
Northwestern University Chicago United States
Pagination or Media Count:
Previous studies of DNA methylation at 5-position of cytosine 5mC have led to the discovery of useful methylation biomarkers for prostate cancer diagnosis and prognosis, some of which are being developed into clinical tests. However, several seminal studies have recently reported that DNA methylation 5mC can be de-methylated by the TET proteins resulting in 5-hydroxylmethylation 5hmC, which plays functional roles distinct from 5mC but yet is indistinguishable from 5mC by a majority of existing methylation assays.